Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study.
Nishibori Y, Kenmotsu H, Ando K, Tonsho A, Matsuda S, Morita M, Sekikawa M, Doshita K, Morikawa N, Miura K, Kodama H, Yabe M, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Harada H, Takahashi T. Nishibori Y, et al. Among authors: mamesaya n. Cancer Treat Res Commun. 2024 Nov 8;41:100849. doi: 10.1016/j.ctarc.2024.100849. Online ahead of print. Cancer Treat Res Commun. 2024. PMID: 39536390 Free article.
Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Morita M, Ono A, Sekikawa M, Doshita K, Miura K, Kodama H, Yabe M, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Kenmotsu H, Naito T, Murakami H, Isaka M, Ohde Y, Takahashi T. Morita M, et al. Among authors: mamesaya n. Cancer Rep (Hoboken). 2024 Sep;7(9):e70004. doi: 10.1002/cnr2.70004. Cancer Rep (Hoboken). 2024. PMID: 39245880 Free PMC article.
Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.
Doshita K, Naito T, Matsuda S, Morita M, Sekikawa M, Miura K, Kodama H, Yabe M, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Murakami H, Kenmotsu H, Takahashi T. Doshita K, et al. Among authors: mamesaya n. Thorac Cancer. 2024 Sep;15(25):1831-1841. doi: 10.1111/1759-7714.15403. Epub 2024 Jul 29. Thorac Cancer. 2024. PMID: 39075850 Free PMC article.
Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study.
Morikawa N, Naito T, Morita M, Sekikawa M, Doshita K, Yabe M, Kodama H, Miura K, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takahashi T. Morikawa N, et al. Among authors: mamesaya n. J Geriatr Oncol. 2024 Sep;15(7):101832. doi: 10.1016/j.jgo.2024.101832. Epub 2024 Jul 12. J Geriatr Oncol. 2024. PMID: 38997933 Free article.
Suitability of frozen cell pellets from cytology specimens for the Amoy 9-in-1 assay in patients with non-small cell lung cancer.
Kodama H, Murakami H, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ko R, Ono A, Kenmotsu H, Naito T, Matsumoto S, Goto K, Shimizu T, Gon Y, Takahashi T. Kodama H, et al. Among authors: mamesaya n. Thorac Cancer. 2024 Jul;15(21):1665-1672. doi: 10.1111/1759-7714.15382. Epub 2024 Jun 19. Thorac Cancer. 2024. PMID: 38898747 Free PMC article.
The efficacy and safety of anamorelin among patients with diabetes.
Ando K, Naito T, Hamauchi S, Miura K, Nishibori Y, Tonsho A, Matsuda S, Morita M, Sekikawa M, Doshita K, Kodama H, Yabe M, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ryo K, Wakuda K, Ono A, Kenmotsu H, Murakami H, Yamazaki K, Takahashi T. Ando K, et al. Among authors: mamesaya n. Int J Clin Oncol. 2024 Aug;29(8):1115-1121. doi: 10.1007/s10147-024-02546-8. Epub 2024 May 9. Int J Clin Oncol. 2024. PMID: 38722487
The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma.
Kanemura H, Yokoyama T, Nakajima R, Nakamura A, Kuroda H, Kitamura Y, Shoda H, Mamesaya N, Miyata Y, Okamoto T, Okishio K, Oki M, Sakairi Y, Chen-Yoshikawa TF, Aoki T, Ohira T, Matsumoto I, Ueno K, Miyazaki T, Matsuguma H, Yokouchi H, Otani T, Ito A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Okamoto I, Nakagawa K, Takeda M. Kanemura H, et al. Among authors: mamesaya n. JTO Clin Res Rep. 2024 Mar 8;5(4):100658. doi: 10.1016/j.jtocrr.2024.100658. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38651033 Free PMC article.
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
Haratani K, Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, Tanizaki J, Tamura Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Tokito T, Nagata K, Masuda T, Nakamura Y, Sakai K, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Haratani K, et al. Among authors: mamesaya n. Br J Cancer. 2024 May;130(11):1783-1794. doi: 10.1038/s41416-024-02662-2. Epub 2024 Mar 22. Br J Cancer. 2024. PMID: 38519705
Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial.
Shimoi T, Sunami K, Tahara M, Nishiwaki S, Tanaka S, Baba E, Kanai M, Kinoshita I, Shirota H, Hayashi H, Nishida N, Kubo T, Mamesaya N, Ando Y, Okita N, Shibata T, Nakamura K, Yamamoto N. Shimoi T, et al. Among authors: mamesaya n. EClinicalMedicine. 2024 Feb 2;69:102447. doi: 10.1016/j.eclinm.2024.102447. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38333370 Free PMC article.
62 results